• Unlocking Opportunity
    in Existing Drugs

    Potentially effective drugs already exist, but
    they’re not getting into clinical trials for the
    diseases where they can do the most good.
    We’re here to change that.


    read more
  • Enabling Development through
    Risk Partnerships

    PCUT BioPartners acquires medically promising drug programs
    that other companies have deprioritized. Our venture partnerships
    allow us to clinically develop them at much lower cost.



    read more

  • Low Cost, High Upside Ventures

    Every existing drug with potential efficacy in diseases
    with unmet medical need is a breakthrough opportunity.
    The venture platform matches these with
    cheap options for investors.



    read more

PCUT BioPartners, Inc.: Clinical Development Where it’s Needed Most

PCUT BioPartners is a commercial developer of early clinical stage drugs. The company licenses in products that have solid medical rationale for efficacy in any of the deadly diseases for which there is no meaningfully effective approved treatment. PCUT BioPartners is a “Venture-Biotech” structure that forms a product development team around each asset, funds the program, and spins off the LLC as a product-specific partnership (PSP). The value prospect is a reduction in front-end costs to enable greater therapy development for patients in need.

World Orphan Innovation Congress
Meet us April 10 - 13
Demo
Meet us March 8 - 9
World Pharma Innovation Congress USA
Recent Event
Demo
International Advocacy
Partnership for Compassionate Use Therapies
Focus on treatments

Sample Cost Partnership

Chart

  • 1% Prospect Sourcing from Non Profit Organizations

  • 24% Product Development Team and Contract Research

  • 25% Contract Manufacturing

  • 50% PCUT BioPartners, Inc.

Click here to download detailed "Cost Partnership PDF"